Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AstraZeneca PLC | ORPATHYS (savolitinib) + TAGRISSO (osimertinib) - (SAFFRON) | Non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | oral | Oncology |
| AstraZeneca PLC | IPH5201 - (MATISSE) | Neoadjuvant lung cancer | Phase 2 | Ongoing | Intravenous | Oncology |
| AstraZeneca PLC | Durvalumab - (NeoCOAST) | Early-stage non-small-cell lung cancer (NSCLC) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| AstraZeneca PLC | AZD1222 (D8110C00001) | COVID-19 vaccine | Phase 3 | Trial Discontinued | Intramuscular | COVID-19 |
| AstraZeneca PLC | AZD2816 | COVID-19 vaccine (variant) | Phase 2/3 | Data Released | Intramuscular | COVID-19 |
| AstraZeneca PLC | tozorakimab - (MIRANDA) | Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Ongoing | intravenous | Respiratory |
| AstraZeneca PLC | FASENRA (Benralizumab) - (RESOLUTE) | Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations | Phase 3 | Trial Discontinued | Subcutaneous | Respiratory |
| AstraZeneca PLC | Gefurulimab - (PREVAIL) | Generalised myasthenia gravis | Phase 3 | Data Released | Intravenous | Neurology |
